62 GlaxoSmithKline Operating and financial review and prospects Operating and financial review and prospects GlaxoSmithKline 63 Global pharmaceutical turnover in the fourth quarter of 2003 Respiratory Pharmaceutical turnover by therapeutic area 2003 declined two per cent, reecting a US turnover decline of GlaxoSmithKline continues to be the global leader in respiratory Total USA Europe International six per cent to 2,188 million: whereas in Europe turnover grew pharmaceuticals with sales of its three key products, Therapeutic area % of 2003 2002 Growth 2003 Growth 2003 Growth 2003 Growth two per cent to 1,363 million, and in International turnover Seretide Advair, Flixotide Flovent and Serevent, amounting to major products total 0 500 1,000 1,500 2000 2,500 3,000 3,500 4,000 m m CER% % m CER% % m CER% % m CER% % grew four per cent to 964 million.
Turnover in the US declined 3.4 billion, up 17 per cent.
Sales of Seretide Advair, the Groups CNS 25 4,455 4,511 4 1 3,112 3 6 847 3 10 496 15 14 due to generic competition to Paxil which began in September largest product, grew 39 per cent to 2.2 billion although this Depression 2,830 2,937 2 4 2,107 1 7 369 8 2 354 25 23 2003. contributed to declines in Serevent and Flixotide, its constituent 9 17 2 23 Seroxat Paxil 1,877 2,055 4 1,179 9 369 8 329 25 products.
Seretide Advair is now one of the top ten pharmaceutical Wellbutrin 953 882 18 8 928 18 8 25 30 25 Pharmaceutical turnover by therapeutic area brands in the world.
798 5 9 11 8 Imigran Imitrex 760 560 1 147 3 53 7 GlaxoSmithKlines ability to continue to deliver pharmaceutical Naramig Amerge 89 90 1 1 49 3 9 32 7 14 8 7 turnover growth, despite generic competition to several of its Seretide also continued to perform strongly in Europe up products, is primarily due to an exceptionally broad product 18 per cent and International markets up 37 per cent.
growth prospects for Advair were further strengthened with an 89 11 24 25 Requip 99 13 47 9 47 15 5 43 Zyban 75 99 25 24 28 35 40 32 12 19 15 45 40 FDA approval for use in the treatment of Chronic Obstructive These include the Respiratory product Seretide Advair 2.2 billion Pulmonary Disease COPD in the fourth quarter 2003. up 39 per cent, the diabetes treatment Avandia Avandamet Respiratory 4,417 3,987 14 11 2,242 21 11 1,481 4 10 694 13 11 24 Flixotide Flovent, 0.9 billion up 24 per cent, Wellbutrin for depression The older respiratory products Ventolin and Becotide continued Serevent, Seretide Advair 3,352 2,937 17 14 1,750 23 12 1,170 7 15 432 18 19 0.9 billion up 18 per cent, the emesis treatment Zofran to decline as patients converted to newer products.
Sales of Trizivir, GlaxoSmithKlines triple Becotide 111 130 16 15 93 15 11 18 23 28 Infanrix Pediarix 0.3 billion up 32 per cent.
combination therapy, grew 22 per cent to 376 million.
Sales in the US Combivir 588 3 11 218 8 17 70 16 9 589 301 3 Global sales of Valtrex, which received FDA approval in August and Europe grew three per cent.
Ziagen 3 15 7 167 173 1 86 6 61 15 20 7 5 Agenerase 44 25 30 39 9 5 3 1 25 Sales of Seroxat Paxil, GlaxoSmithKlines leading product for 31 19 33 depression and anxiety disorders, declined four per cent to Anti-bacterials 653 Herpes 669 6 2 325 15 5 148 3 6 196 2 4 1,877 million.
US sales declined nine per cent to 1,179 million Anti-bacterial sales declined 16 per cent worldwide and Valtrex 425 17 15 9 499 23 316 26 86 18 97 25 26 following the launch of a generic paroxetine in September 2003.
Augmentins US sales were down Zovirax 228 26 25 74 62 16 7 99 19 22 170 9 72 By January 2004, GlaxoSmithKline's innovative new product Paxil 51 per cent in the year as a result of generic competition that Zeffix 129 123 11 5 10 4 17 17 2 6 102 14 7 CR increased its share of total Paxil prescriptions branded and began in the third quarter 2002. generic since the generic launch from 33 per cent to 37 per cent.
10 Anti-bacterials 2,210 16 18 41 46 755 1 8 536 1 In the USA, GlaxoSmithKlines two new antibiotics, Augmentin ES 1,815 524 6 Paxil CR sales in 2003 were 387 million.
Europe Paxil sales Augmentin 825 1,191 29 31 51 56 332 2 5 181 11 5 312 for children, and Augmentin XR for adults, recorded combined declined eight per cent to 369 million reecting competition Zinnat Ceftin 246 243 1 22 29 35 134 6 15 90 4 2 sales of 237 million in 2003 in spite of generic competition.
International sales grew 25 per cent to Amoxil 136 11 14 36 41 36 26 20 62 5 117 19 15 329 million led by continued strong growth in Japan.
Metabolic Metabolic 6 1,079 960 20 12 755 20 10 116 32 38 208 16 11 Sales of Wellbutrin, for depression, grew 18 per cent to Worldwide sales for the metabolic category were 1.1 billion, up Avandia Avandamet 931 809 24 15 755 20 10 70 57 67 106 40 34 953 million, reecting increased physician awareness of the 20 per cent.
The Avandia franchise Avandia and Avandamet products outstanding efcacy and favourable side-effect prole.
This formulation accounted for 40 per cent of Avandamet, a combination of Avandia and metformin HCI, branded Wellbutrin prescriptions in early February 2004 and Oncology and emesis 6 1,001 977 9 2 743 10 163 7 95 12 1 13 expanded the Avandia metabolic franchise with its US launch in seven per cent of sales in 2003.
In Europe, Avandia has benefited from Hycamtin 110 94 23 17 77 33 22 25 4 8 14 14 Limited generic competition to Wellbutrin began in the USA in increasing physician acceptance with sales of 70 million, up Cardiovascular and January 2004 for the 100mg dose.
Generic competition across all 57 per cent.
The franchise should benefit further from the EU 4 urogenital 771 661 22 17 495 24 14 176 10 20 100 34 28 dose forms of Wellbutrin SR is expected at any time.
approval of Avandamet in December 2003.
Avandia also did very Coreg 361 306 28 18 346 28 17 15 33 36 well in International markets with sales of 106 million, up Levitra 37 22 11 4 GlaxoSmithKlines medicine for epilepsy, Lamictal, continued to Avodart 6 40 per cent.
19 100 100 14 100 100 5 grow across all regions achieving sales of 556 million, up 31 per cent.
In June 2003, the FDA approved Lamictal for long- 6 Other 1,171 1,310 8 11 99 15 22 355 16 13 717 3 8 Vaccines term maintenance treatment of bi-polar disorder.
Zantac 328 382 13 14 77 1 10 94 25 19 157 10 13 Sales of vaccines grew two per cent to 1.1 billion, supported by the Infanrix Pediarix franchise, up 32 per cent to 336 million.
The 100 18,181 17,995 5 1 9,410 5 4 5,114 9 3,657 5 2 8 hepatitis franchise declined 13 per cent to 417 million reecting competitive pressure in the USA and Europe.
CER% represents turnover growth at constant exchange rates.
% represents growth at actual exchange rates.
An analysis of turnover by quarter is given in the Financial record pages 152 to 155.
In the USA, GlaxoSmithKlines new Pediarix vaccine was launched in January 2003.
Pediarix adds protection against hepatitis B and poliomyelitis to the Infanrix combination and results in up to six fewer injections for infants.
64 GlaxoSmithKline Operating and financial review and prospects Operating and financial review and prospects GlaxoSmithKline 65 Cardiovascular and urogenital As a result, management believes that within the European region USA International In 2003, Coreg sales grew 28 per cent to 361 million, benefiting turnover by market, on an invoiced basis as presented above, does The USA reported five per cent turnover growth in the year and An eight per cent turnover growth in the International region from recent data that showed a highly significant statistical not properly represent the consumption of the products within this business represents 52 per cent of total pharmaceutical reected a mixture of good growth in the Middle East and Africa, difference in survival between Coreg and metopropol in patients each market.
GlaxoSmithKline staff based in each market are turnover.
Canada, Japan and Asia Pacic.
Latin America also grew strongly with heart failure.
instrumental in the promotion of the Groups products within their as Mexico rebounded following poor economic conditions and a Advair maintained its strong growth with sales of 1,235 million market, thereby creating a product sale and final consumption in re-alignment of wholesaler stock levels in 2002.
Levitra vardenal, a new agent for the treatment of erectile driving the overall respiratory growth of 21 per cent.
The table below gives the adjustments made in order dysfunction, was launched in the USA in August 2003 and in this adversely affected sales of its constituent products, Flovent Overall International growth was driven by Seretide, Seroxat Paxil to restate the turnover for markets within Europe on a turnover Europe in the first half of the year.
Levitra was researched and and Serevent, which both showed declines.
Flonase indicated for and Avandia, partly offset by declines in Zantac and Zovirax.
These adjustments are GlaxoSmithKline estimates developed by Bayer AG and is co-promoted with GlaxoSmithKline.
the treatment of perennial rhinitis grew strongly by 22 per cent.
based on the most recent data from independent external sources, The Asia Pacic area grew due to the performance of Seretide valued in sterling at relevant exchange rates.
Management believes Sales growth of three per cent in the central nervous system and Avandia.
Strong growth in a number of markets was partly Oncology and emesis that this turnover created basis of reporting turnover by market products included sales of Wellbutrin up 18 per cent, reecting offset by a decline of one per cent in the largest market, Australia, Sales of Zofran grew 16 per cent to 774 million, driven by a provides a better reection of the performance of the businesses the performance of the new once a day formulation Wellbutrin XL.
reecting reduced sales of Zyban, Zantac and the older antibiotics.
strong US performance, up 20 per cent to 575 million.
in each market within Europe.
Paxil sales declined nine per cent due to the launch of generic The growth in Japan reected strong growth of Paxil, Serevent paroxetine in September 2003.
By January 2004, GlaxoSmithKline's Other therapeutic areas The total turnover for Europe region is unaffected by this and Valtrex partly offset by the declines of Zovirax, Zantac, and innovative new product Paxil CR increased its share of total Paxil Sales of Zantac fell 13 per cent to 328 million with declines in restatement.
prescriptions branded and generic since the generic launch all regions.
Parallel trade occurs occasionally elsewhere in the world but it is from 33 per cent to 37 per cent.
Paxil CR sales in 2003 were The Middle East and Africa area followed the trends of most not sufciently material to affect signicantly the turnover data by 387 million.
other markets with growth in Seretide, Avandia, and vaccines.
In Regional analysis market presented on an invoiced basis.
Canada growth was driven by Seretide and Avandia.
Sales in the anti-virals therapeutic area grew four per cent with The turnover reported in the table below represents sales invoiced HIV led by a strong performance of Trizivir up 20 per cent, which by GlaxoSmithKlines local entity to its customers in the local Consumer Healthcare sales Pharmaceutical turnover for Europe region in 2003 - partially drew sales from its constituent products.
Valtrex, for 2003 2002 Growth market plus co-promotion income within each market.
reconciliation of adjustment for parallel trade m m CER% % herpes, grew 26 per cent driven by the FDA approval for the 2003 2002 Pharmaceutical turnover by geographic region in 2003 reduced risk of transmission of genital herpes.
OTC medicines 1,556 1,586 2 2 Region Invoiced Adjustment Created Invoiced Adjustment Created on an invoiced basis major markets m Analgesics 342 339 4 1 m m m m m Sales of Avandia increased by 20 per cent, benefiting from the 2002 Growth Region % of 2003 Dermatological 237 188 31 26 launch of Avandamet in November 2002.
Coreg sales increased 28 per cent Italy 660 8 652 593 29 564 Smoking control 325 378 8 14 Europe 28 5,114 4,701 2 9 reecting the benefit from recent data that showed a highly Germany 538 59 597 502 47 549 France 9 1,005 918 4 Natural wellness support 166 162 3 2 Spain significant statistical difference in survival between Coreg and 528 21 507 502 24 478 UK 11 731 658 20 Central & 421 421 401 401 metopropol in patients with heart failure.
Italy 593 1 11 660 Oral care 1,082 1,052 3 3 Eastern Europe Germany 538 502 8 7 Other Europe 1,231 51 1,180 1,127 67 1,060 Spain 5 Nutritional healthcare 622 579 9 7 528 502 8 Europe Central & 7 5 421 401 Turnover by market within Europe has been adjusted for the effects The discussion of individual market performance in the Europe 3,260 3,217 4 1 Eastern Europe of parallel trade to show turnover on the basis of the country region is on a turnover created basis rather than a turnover 9 Other Europe 1,231 1,127 4 The growth in Consumer Healthcare sales of four per cent to where the product is nally consumed, not where the product was invoiced basis.
8 5 International 3,657 3,497 20 3,260 million comprised an OTC medicines sales increase of sold by GlaxoSmithKline.
6 4 Asia Pacific 1,140 1,100 Europe region contributed 28 per cent of pharmaceutical turnover.
two per cent, a Nutritional healthcare sales increase of nine per 6 712 8 Japan 753 Although overall turnover growth in the region was only two cent and Oral care sales increase of three per cent.
13 1 Latin America 606 597 per cent, good growth was recorded in Italy and Central and Pharmaceutical turnover by geographic region in 2003 7 6 Middle East, Africa 693 652 on a turnover created basis Eastern Europe, but government healthcare reforms, including 8 11 Canada 474 427 OTC medicines Growth 2003 2002 pricing and reimbursement restrictions, adversely affected turnover Region % of Over-the-counter medicine sales were 1.6 billion, up two per cent.
Seretide, GlaxoSmithKlines largest Sales of smoking control and gastro-intestinal products were CER% represents turnover growth at constant exchange rates.
% represents growth at 4 selling product in Europe, reported notable growth in France, Italy USA 52 9,410 9,797 5 down signicantly in the USA primarily due to at market conditions actual exchange rates.
An analysis of turnover by quarter is given in the Financial record and the UK, although this was partly offset by expected declines in and to private label competition.
Growth from smoking control pages 152 to 155.
Trizivir showed strong growth in all of the France 966 867 1 11 products recently launched in Europe and sales of dermatological UK Individual governments determine the pricing of medicines in most 791 782 1 1 major markets in the region.
The decline in sales of the herpes products acquired earlier this year helped to offset these declines.
Italy 6 16 652 564 countries within Europe, which can result in wide price variations franchise was mainly as a result of generic competition for Zovirax Germany 549 1 9 597 for the same product.
Parallel trade occurs when third parties partially offset by patients switching to the newer Valtrex product.
Oral care Spain 507 478 3 6 exploit this price differential by purchasing products in the market Central & 421 401 7 5 Oral care sales were 1.1 billion, up three per cent.
Eastern Europe where low prices are enforced and selling them to governments GlaxoSmithKline's Sensodyne brand continues to grow in all Other Europe 1,180 1,060 2 11 and other purchasers in those markets where higher prices have regions.
This parallel trade is permitted under the single International 20 3,497 3,657 8 5 market rules in the European Union.
GlaxoSmithKline does not Asia Pacific 1,140 1,100 6 4 Nutritional healthcare Japan 753 712 8 6 derive any benefit from the profit on resale at the higher price.
Nutritional healthcare products grew nine per cent to 0.6 606 Latin America 597 13 1 billion.
Lucozade Sport and Lucozade Hydroactive continued to Middle East, Africa 652 693 7 6 Canada 474 427 8 11 drive growth in this category.
18,181 17,995 5 1 100 CER% represents turnover growth at constant exchange rates.
66 GlaxoSmithKline Operating and financial review and prospects Operating and financial review and prospects GlaxoSmithKline 67 Trading profit statutory results profit before taxation - statutory results Trading profit business performance profit before taxation - business performance Statutory results include merger items, integration and The analysis and discussion below of profit before taxation relates To illustrate GlaxoSmithKline business performance in 2003, the The analysis and discussion below of profit before taxation relates restructuring costs, and the disposal of subsidiaries.
analysis below of trading profit and the subsequent discussion to business performance.
excludes merger items, integration and restructuring costs and the 2003 2002 Growth 2003 2002 2003 2002 Other operating income expense m m Other operating income expense m m disposal of businesses.
Management believes that exclusion of m % m % CER% % these items provides a better reection of the way in which the Royalties and other income 75 75 Royalties and other income 75 75 Turnover 21,441 100.0 21,212 100.0 5 1 business is managed.
Accordingly this information is provided as a Other operating expense 436 209 Other operating expense 436 209 Cost of sales 4,544 21.2 4,609 21.7 1 supplement to that contained in the consolidated statement of 361 134 361 134 Selling, general profit and loss on pages 88 and 89 prepared in accordance with Income from equity investments and Income from equity investments and and administration 7,581 35.4 8,041 37.9 2 6 UK GAAP.
other disposals 228 23 other disposals 228 23 Research and development 2,791 13.0 2,900 13.7 1 4 133 111 2003 2002 Growth 133 111 m % m % CER% % Trading profit 6,525 30.4 5,662 26.7 21 15 Other operating income expense includes litigation costs and Other operating income expense includes litigation costs and Turnover 21,441 100.0 21,212 100.0 5 1 provisions relating to legal claims on withdrawn products, provisions relating to legal claims on withdrawn products, product Cost of sales 4,188 19.5 4,243 20.0 1 Cost of sales product withdrawals and anti-trust matters, equity investment withdrawals and anti-trust matters, equity investment carrying Selling, general Cost of sales reduced as a percentage of turnover as a result of carrying value adjustments arising from stock market price value adjustments arising from stock market price changes, royalty and administration 7,563 35.3 7,543 35.5 4 benets arising from merger and manufacturing restructuring changes, royalty income, product disposals and equity income, product disposals and equity investment sales.
Research and savings and a favourable product mix.
A small pricing benefit was investment sales.
Other operating expenses were 133 million in the year compared development 2,770 12.9 2,732 12.9 4 1 more than offset by an adverse exchange impact.
Merger and Other operating expenses were 133 million in the year with 111 million in 2002.
The year-on-year movement reects manufacturing costs incurred of 356 million were 10 million Trading profit 6,920 32.3 6,694 31.6 9 3 compared with 111 million in 2002.
The year on year higher provisions in 2003 for product liability, anti-trust and other lower than in 2002. movement reects higher provisions in 2003 for product liability, claims, partially offset by higher 2003 proceeds from product Cost of sales anti-trust and other claims, partially offset by higher 2003 disposals and equity investment sales.
Selling, general and administration Cost of sales reduced as a percentage of turnover as a result of proceeds from product disposals and equity investment sales.
Selling, general and administration SG&A costs declined two per benets arising from merger, manufacturing restructuring savings, Share of profits losses of joint ventures and associated cent reecting reduced merger integration costs and operational Business disposals and a favourable product mix.
A small pricing benefit was more undertakings excellence cost savings initiatives.
These were partly offset by The profit on disposal of businesses in 2003 of 5 million reects than offset by an adverse exchange impact.
The share of profits of associates arises principally from the Groups increased selling costs to support new product launches, charges the final settlements regarding the disposal of Healthcare holding in Quest Diagnostics, Inc. relating to cost saving programmes and increased pension costs.
Selling, general and administration Without the merger integration costs SG&A grew four per cent 2003 2002 Selling, general and administration SG&A costs grew four per Net interest payable m m driven by selling cost increases, which accounted for a three Share of profits losses of joint ventures and associated cent reecting increased selling costs to support new product percentage point increase.
The charges relating to operational Interest payable 214 206 undertakings launches, charges relating to operational excellence cost saving excellence and pension cost increases each individually added one Investment income 61 73 The share of profits of associates arises principally from the programmes and increased pension costs, partly offset by cost percentage point, while cost savings reduced growth by one Groups holding in Quest Diagnostics, Inc. saving initiatives.
These cost saving initiatives were relatively small 153 133 percentage point.
Together these produced a reduction of 2003 2002 restructuring activities in 2002 and 2003.
It is estimated that Share of interest payable of associate 8 8 Net interest payable m m 2.5 percentage points relative to 2002 for the expenses expressed without the operational excellence charges SG&A would have 161 141 as a percentage of turnover.
Interest payable 214 206 grown three per cent, driven principally by selling cost increases.
Investment income 61 73 Pension cost increases added one percentage point, but these were Net interest payable increased compared with 2002 largely as a Research and development 153 133 offset by cost saving initiatives.
Together these produced a result of the unwinding of the discounts on provisions and longR&D declined one per cent reecting reduced merger integration Share of interest payable of associate 8 8 reduction of 0.2 percentage points expressed as a percentage of term receivables.
costs, partly offset by increased clinical trial and in-licensing activity turnover.
161 141 and the reinvestment of merger synergies.
Pharmaceuticals R&D profit on ordinary activities before taxation - business expenditure represented 14.9 per cent of pharmaceutical turnover Net interest payable increased compared with 2002 largely as Research and development performance in the year.
a result of the unwinding of the discounts on provisions and Research and development R&D increased four per cent reecting Taking account of net other operating income expense, the long-term receivables.
increased clinical trial and in-licensing activity and the reinvestment contribution from associates and net interest payable, business Trading profit of merger synergies.
Pharmaceuticals R&D expenditure represented performance profit before tax was 6,719 million, compared with Statutory trading profit was 6,525 million with a growth of profit on ordinary activities before taxation - statutory 14.8 per cent of pharmaceutical turnover in the year.
6,517 million in 2002, an increase of eight per cent.
21 per cent, stronger than turnover growth of five per cent, results demonstrating an improved trading margin of 3.7 percentage Taking account of net other operating income expenses, the Trading profit Merger items, restructuring costs and disposal of businesses points.
This was principally due to lower merger integration costs, contribution from associates, business disposals and net interest Business performance trading profit was 6,920 million with a cost savings derived from merger integration, manufacturing and Merger and manufacturing restructuring payable, statutory profit before tax was 6,329 million compared growth of nine per cent, stronger than turnover growth of five per other initiatives partly offset by charges relating to operational GlaxoSmithKline has made good progress with its merger and with 5,506 million in 2002, an increase of 21 per cent.
cent, demonstrating an improved trading margin of 0.7 points to excellence cost saving programmes and higher pension costs.
The merger programmes are 32.3 per cent compared with 2002.
This was principally due to cost substantially complete at the end of 2003.
Combined these savings derived from merger integration, manufacturing and other programmes have now produced annual savings which exceeded initiatives, partly offset by charges relating to operational excellence the published target of 1.8 billion.
cost saving programmes and higher pension costs.
Costs of 369 million were incurred in the year in respect of The focus of operational excellence is on value creation and the merger and manufacturing restructuring.
After tax relief of elimination of waste and bureaucracy.
This programme has become 91 million, the net charge was 278 million.
The costs in 2003 an integral part of the way the business is managed and so any include severance, asset write-downs, professional fees and site charges are booked to business performance.
68 GlaxoSmithKline Operating and financial review and prospects Operating and financial review and prospects GlaxoSmithKline 69 Block Drug Company, Inc. GlaxoSmithKline uses the best advice in determining its transfer Critical accounting policies Impairment of xed assets GlaxoSmithKline acquired Block Drug in January 2001.
The costs pricing methodology and in seeking to manage transfer pricing The carrying values of xed assets subject to depreciation and The consolidated financial statements are prepared in accordance incurred in integrating this business were 26 million in 2003 issues to a satisfactory conclusion and, on the basis of external amortisation are reviewed for impairment when there is an with UK generally accepted accounting principles, following the including redundancies, asset write-downs and site closures.
professional advice, continues to believe that it has made adequate indication that the values of the assets might be impaired.
accounting policies approved by the Board and described in provision for the liabilities likely to arise from open assessments.
Impairment is determined by reference to the higher of net Note 2 to the Financial statements, Accounting policies.
Disposal of businesses However, there continues to be a wide difference of views realisable value and value in use, measured by reference to Management is required to make estimates and assumptions that The profit on disposal of businesses in 2003 of 5 million reects between the Group and the IRS.
The ultimate liability for such risk-adjusted future cashows discounted using appropriate riskaffect the amounts of assets, liabilities, revenue and expenses the final settlements regarding the disposal of the Healthcare matters may vary signicantly from amounts provided and is free interest rates.
These future cashows are based on business reported in the financial statements.
Actual amounts and results Services businesses in 1999. dependent upon the outcome of litigation proceedings and forecasts and are therefore inherently judgemental.
Future events could differ from those estimates.
The following are considered to negotiations with the relevant tax authorities.
could cause the assumptions used in these impairment reviews to be the critical accounting policies adopted.
Taxation change with a consequent adverse effect on the future results of The credit for taxation on merger and restructuring items 2003 2002 the Group.
m m amounting to 109 million reects the actual tax rate applicable Turnover to the transactions in the territories in which they arise.
Gross turnover is reduced by discounts and allowances which vary Business performance 1,848 1,760 Investment in own shares by product arrangements and buying groups.
These arrangements Merger, restructuring and disposal GlaxoSmithKline has invested in its own shares through Employee Earnings Growth with purchasing organisations are dependent upon the submission of subsidiaries 109 299 2003 2002 CER% % Share Ownership Trusts in order to meet obligations arising from of claims some time after the initial recognition of the sale.
A Total 1,739 1,461 certain of the companys employee share option schemes.
These Statutory earnings m 4,484 3,915 20 15 provision is made at the time of sale for the estimated discount or shares are held at cost, less a provision to recognise any shortfall Basic earnings per share 77.2p 66.2p 23 17 allowance payable based on historical experience.
These amounts in the proceeds receivable from the employee on exercise, unless The integrated nature of the Groups worldwide operations, Basic earnings per ADS $2.53 $1.99 23 27 are subject to change dependent upon, amongst other things, the management believes there to be a permanent impairment in involving significant investment in research and strategic types of buying group and product sales mix.
The level of provision Adjusted earnings m 4,765 4,627 8 3 their value in relation to the period of time over which the related manufacture at a limited number of locations, with consequential is reviewed regularly in the light of historical experience of actual Adjusted earnings per share 82.1p 78.3p 10 5 share options may be exercised.
Any impairment would have an cross-border supply routes into numerous end-markets, gives rise discounts or allowances given and any changes in arrangements.
Adjusted earnings per ADS $2.69 $2.35 10 14 adverse effect on the results of the Group in that accounting to complexity and delay in negotiations with revenue authorities Future events could cause the assumptions on which the discounts period.
In 2004, following a change in UK accounting as to the profits on which individual Group companies are liable Weighted average number are based to change, which could affect the future results of the requirements, these shares will be shown as a deduction from to tax.
Disagreements with, and between, revenue authorities as of shares millions 5,806 5,912 Group.
equity shareholders funds and will no longer be subject to to intra-Group transactions, in particular the price at which goods potential impairment.
Adjusted earnings and adjusted earnings per share are presented should be transferred between Group companies in different tax Legal and other disputes above in order to illustrate business performance which is the jurisdictions, can produce conicting claims from revenue GlaxoSmithKline provides for anticipated settlement costs and Pensions and post-retirement benets primary measure used by management.
Adjusted earnings authorities as to the profits that fall to be taxed in individual associated expenses arising from asserted claims against the Group The costs of providing pensions and other post-retirement benets increased by eight per cent.
Adjusted earnings per share increased territories.
Resolution of such issues is a continuing fact of life where a reasonable estimate may be made of the likely outcome are charged to the profit and loss account in accordance with by 10 per cent reecting the reduction in the weighted average for GlaxoSmithKline.
The Group has open issues with the revenue of the dispute.
The companys Directors, having taken legal advice, SSAP 24 over the period during which benefit is derived from the number of shares resulting from the Groups share buy-back authorities in the USA, UK, Japan and Canada, but by far the have established provisions after taking into account insurance employees services.
The costs are assessed in accordance with programme.
The interest cost of this programme also impacts the largest relates to Glaxo heritage products in the USA.
and other agreements and having regard to the relevant facts and advice received from independent actuaries on the basis of Groups earnings.
circumstances of each matter and in accordance with accounting In the USA, for a number of years, GlaxoSmithKline has had assumptions selected by management.
These assumptions include At actual rates of exchange, adjusted earnings per share increased requirements.
No provisions have been made for unasserted claims significant open issues relating to transfer pricing.
GlaxoSmithKline future earnings and pension increases, discount rates and expected five per cent in sterling terms, compared with 10 per cent in CER or for claims for which no reasonable estimate of the likely has attempted to settle the dispute, first through direct discussion long term rates of return on assets and are disclosed in Note 33 terms.
The adverse currency impact on EPS of five per cent in the outcome can yet be made.
The ultimate liability for pending and with the US Internal Revenue Service IRS and subsequently to the Financial statements, Employee costs.
The expected long year reected the significant weakening of the US dollar relative unasserted claims may vary from the amounts provided, if any, and through discussions between the USA and UK authorities under term rates of return on assets are determined based on long term to 2002 and compares with a four per cent adverse currency is dependent upon the outcome of litigation proceedings, the terms of the double tax convention between the two countries.
government bond rates adjusted for risk and current market impact on turnover.
This difference principally arises from a investigations and possible settlement negotiations.
GlaxoSmithKline understands that the views of the two tax expectations.
This Note also gives the additional disclosures different mix of currencies in profits compared with turnover.
authorities were so different that they were unable to reach required by FRS 17 Retirement Benets.
The selection of different Intangible assets agreement, and discussions were terminated in July 2003. assumptions could affect the future results of the Group.
Taken together with other expenses, taxation and business Where intangible assets are acquired by GlaxoSmithKline from disposals this resulted in a basic EPS of 77.2 pence compared with The Group has now received a claim for additional taxes that the third parties the costs of acquisition are capitalised.
Licences to Product rights and goodwill 66.2 pence in 2002 and a diluted EPS of 77.0 pence compared IRS asserts legacy company Glaxo Wellcome owes for the years compounds in development are amortised over their estimated In addition to the critical accounting policies outlined above, the with 66.0 pence in 2002.
Merger and manufacturing restructuring 1989 to 1996.
This statutory notice of deficiency for $2.7 billion useful lives, but not exceeding 15 years.
Estimated useful lives are accounting policy for product rights and goodwill is deemed to costs were lower in 2003 than in 2002 and as a result, the sterling 1.5 billion in tax principally relates to the allocation of profits reviewed annually and impairment reviews are undertaken if be important in respect of the balance sheet prepared in based growth in basic EPS of 17 per cent was signicantly higher for Glaxo heritage products between the USA and other countries.
events occur which call into question the carrying values of the accordance with US accounting principles.
Under US GAAP the than the CER based growth in adjusted EPS despite the overall To the extent that the IRS were successful in its claim, interest assets.
Brands acquired with businesses are capitalised merger of Glaxo Wellcome and SmithKline Beecham in 2000 was negative impact of currencies in 2003. would be payable.
GlaxoSmithKline estimates the interest on the independently where they are separable and have a long-term accounted for as an acquisition which gave rise to product rights full claim to date would be approximately $2.5 billion 1.4 billion, value to the Group.
Brands are amortised over their estimated of 24 billion and goodwill of 16 billion being recognised.
Dividend net of federal tax relief.
As similar tax issues remain open for 1997 useful lives, not exceeding 20 years, except where the end of the Goodwill and those product rights determined to have indefinite The Board has declared a fourth interim dividend of 14 pence per to date, GlaxoSmithKline expects to receive further claims by the useful economic life cannot be foreseen.
Where brands are not lives are not amortised but rather reviewed annually for share making a total for the year of 41 pence per share.
amortised, they are subject to annual impairment reviews.
These impairment reviews assess business projections compares with a total dividend of 40 pence per share for 2002.
Impairment reviews are based on risk-adjusted future cash ows Since GlaxoSmithKline has exhausted all administrative remedies prepared as part of the Groups annual budgeting and planning In 2004, GlaxoSmithKline expects a similar increase in the total discounted using appropriate risk-free interest rates.
These future open to it, the company plans to contest this claim for additional process to determine whether or not an impairment in the value of dividend as has been declared in 2003.
The allocation of the cash ows are based on business forecasts and are therefore taxes by ling a petition in the US Tax Court, where a trial is not the goodwill has occurred.
The business projections include quarterly dividends will be rebalanced in 2004.
Future events could cause the values of expected until sometime in 2005 or 2006. assumptions about future events.
Changes in future events could intends to increase the first three interim dividends from nine these intangible assets to be impaired and this would have an cause the assumptions in the business projections to change with a GlaxoSmithKline continues to believe that the profits reported by pence to 10 pence, with the remainder of the total dividend for adverse effect on the future results of the Group.
consequent adverse effect on the future results of the Group as the US subsidiaries for the period 1989 to date, on which it has the year being allocated to the fourth quarter dividend.
paid taxes in the USA, are more than sufficient to reect the activities of its US operations.
70 GlaxoSmithKline Operating and financial review and prospects Operating and financial review and prospects GlaxoSmithKline 71 Financial position and resources Financial position Debtors Commitments and contingent liabilities It is the Groups policy to provide for the settlement costs of Debtors increased in 2003 reecting the timing of year-end Financial commitments are summarised in Note 26 to the Financial asserted claims and environmental disputes when a reasonable 2003 2002 m m receipts, a higher deferred tax asset, insurance receivables and statements, Commitments.
Other contingent liabilities and estimate may be made.
Prior to this point no liability is recorded.
additional cash contributions into the UK pension plan.
obligations in respect of short and long-term debt are set out in Legal and environmental costs are discussed in Risk factors on Goodwill 143 171 Note 24 to the Financial statements, Contingent liabilities and pages 74 to 76.
Intangible xed assets 1,697 1,637 Provisions Note 25 to the Financial statements, Net debt.
Tangible xed assets 6,441 6,649 GlaxoSmithKline uses the best advice in determining its transfer The Group carried provisions of 3,030 million at 31st December Investments 3,069 3,121 Amounts provided for pensions and post-retirement benets, pricing methodology and, on the basis of external professional 2003 in respect of estimated future liabilities, of which 1,007 Fixed assets 11,350 11,578 restructuring and integration plans and legal, environmental and advice, continues to believe that it has made adequate provision million related to legal and other disputes and 807 million other disputes are set out in Note 23 to the Financial statements, for the liabilities likely to arise from open taxation assessments.
related to pensions and other post-retirement benets for Equity investments 164 161 Provisions for liabilities and charges.
The ultimate liability for such matters may vary signicantly from employees.
Provision has been made for tax, legal and other Stocks 2,109 2,080 amounts provided and is dependent upon the outcome of litigation disputes, indemnified disposal liabilities and the costs of Debtors 6,897 6,200 Contractual obligations and commitments proceedings and negotiations with the relevant tax authorities.
manufacturing restructuring and merger integration to the extent Liquid investments 2,493 1,256 The following table sets out the Groups contractual obligations This is discussed further in Note 12 to the Financial statements, that at the balance sheet date an actual or constructive obligation Cash at bank 962 1,052 and commitments as they fall due for payment.
existed and could be reasonably estimated.
Current assets 12,625 10,749 Total Under 1 yr 1-3 yrs 3-5 yrs 5 yrs Cash ow Loans and overdrafts 1,452 1,551 m m m m m Net debt Other creditors 7,145 7,257 Group net debt at 31st December comprised: A summary of the consolidated cash ow statement is set out Loans 5,090 1,451 840 1,198 1,601 Creditors: amounts due within one year 8,597 8,808 2003 2002 below: Finance lease obligations 13 1 3 3 6 m m Operating lease 2003 2002 Net current assets 4,028 1,941 m m Cash and liquid investments 3,455 2,308 commitments 547 120 172 97 158 Borrowings repayable within one year 1,452 1,551 Total assets less current liabilities 15,378 13,519 Intangible xed assets 1,412 150 252 312 698 Net cash inow from operating activities 7,005 7,255 Borrowings repayable after one year 3,651 3,092 Tangible xed assets 171 155 16 Dividends from joint ventures and Loans 3,651 3,092 Other commitments 144 58 55 31 associated undertakings 1 2 Net debt 1,648 2,335 Other creditors 232 206 Returns on investment and servicing Total 7,377 1,935 1,338 1,641 2,463 Creditors: amounts due after one year 3,883 3,298 Net debt decreased in 2003 to 1,648 million primarily due to of finance 231 237 Provisions for liabilities and charges 3,030 2,833 lower purchases of shares by the company for cancellation, partly The Group has entered into a number of research collaborations Taxation paid 1,917 1,633 offset by an increase in working capital.
Net assets 8,465 7,388 to develop new compounds with other pharmaceutical companies.
Capital expenditure and financial investment 928 1,120 The terms of these arrangements can include up-front fees, equity Acquisitions and disposals 12 20 Called up share capital 1,487 1,506 Pensions investments, loans and commitments to fund specified levels of Equity dividends paid 2,333 2,327 Share premium account 264 224 The Group continues to account for pension arrangements in research.
In addition the Group will often agree to make further Net cash inow outow before management Other reserves 1,925 1,905 accordance with SSAP 24.
Under the transitional provisions of payments if future milestones are achieved.
As some of these of liquid resources and nancing 1,585 1,920 profit and loss account 4,044 2,946 FRS 17 the disclosed pension assets and liabilities of the Group at agreements relate to compounds in the early stages of Management of liquid resources 1,336 52 31st December 2003 show a net deficit after allowing for deferred Equity shareholders funds 7,720 6,581 development, milestone payments will continue for a number of Financing 276 1,567 taxation of 1,300 million 2002 1,262 million.
In the fourth years if the compounds move successfully through the Decrease increase in cash in the year 27 405 Non-equity minority interests 503 559 quarter of 2003 special cash contributions of 314 million were development process.
Generally the closer the product is to Equity minority interests 242 248 made to reduce the funding deficit.
marketing approval the greater the possibility of success.
The Reconciliation of net cash ow to movement in net debt payments shown above represent the maximum that would be Capital employed 8,465 7,388 The company will review this position annually and will make paid if all milestones are achieved.
A number of commitments 2003 2002 further contributions as appropriate.
m m Investments were made in 2003 under licensing and other agreements, GlaxoSmithKline had investments, excluding own shares, at Net debt at beginning of year 2,335 2,101 principally with NeuroSearch A S, Ranbaxy Laboratories Ltd. and Shareholders funds 31st December 2003 with a carrying value of 458 million Decrease increase in cash in the year 27 405 POZEN Inc. Pension commitments are provided in Note 33 to A summary of the movements in equity shareholders funds is set 2002 456 million.
The market value at 31st December 2003 Cash inow outow from management the Financial statements, Employee costs.
The investments, of liquid resources 1,336 52 2003 2002 which include associates and joint ventures, are mainly in equity Net increase in long-term loans 1,023 1,005 Contingent liabilities m m shares where the holding derives directly from the Groups Net repayment of short-term loans 442 542 The following table sets out contingent liabilities, comprising At beginning of year 6,581 7,390 business.
These investments include stakes in companies where Exchange and other movements 41 124 discounted bills, performance guarantees and other items arising profit for the year 4,484 3,915 the Group has research collaborations, which provide access to in the normal course of business and when they are expected to Net debt at end of year 1,648 2,335 Dividends 2,374 2,346 biotechnology developments of potential interest or interests in expire.
Shares issued on exercise of share options 41 56 companies that arise from business divestments.
The net cash inow from operating activities was 7,005 million, Total Under 1 yr 1-3 yrs 3-5 yrs 5 yrs Shares purchased and cancelled 980 2,220 m m m m m a decrease of 250 million over 2002, arising from the timing of Exchange movements 30 154 Own shares trade and other receipts over the year-end period and higher Guarantees 207 47 13 147 UK tax: exchange movements and At 31st December 2003 the ESOTs held 177.8 million payments for legal and other provisionable items, partly offset by Other contingent liabilities 29 12 4 2 11 unrealised gains 69 67 GlaxoSmithKline shares, at a carrying value of 2,775 million and reduced restructuring and integration payments.
Total 236 59 17 2 158 Unrealised gain on equity investments 7 7 market value of 2,276 million, against the future exercise of Capital expenditure on tangible and intangible xed assets share options and share awards.
This valuation shortfall is not At end of year 7,720 6,581 In the normal course of business the Group has provided various amounted to 1,062 million 2002 1,226 million.
Disposals considered to represent a permanent diminution in value in the indemnification guarantees in respect of business disposals in realised 46 million 2002 59 million.
Equity investments context of the length of the future period over which the related Equity shareholders funds increased from 6,581 million at which legal and other disputes have subsequently arisen.
A costing 63 million 2002 75 million were purchased in the share options may be exercised.
Accordingly no provision has 31st December 2002 to 7,720 million at 31st December 2003. provision is made where a reasonable estimate can be made of year and sales of equity investments realised 125 million been made.
The increase arises from retained earnings and positive exchange the likely outcome of the dispute and this is included in Note 23 2002 65 million.
movements on overseas net assets partly offset by own shares to the Financial statements, Provisions for liabilities and charges.
72 GlaxoSmithKline Operating and financial review and prospects Operating and financial review and prospects GlaxoSmithKline 73 No shares of GlaxoSmithKline plc were purchased by the ESOTs Liquidity Funding, maturity and counterparty risk The Group uses a limited number of interest rate swaps to in 2003 to satisfy future exercises of options and awards under The Group operates globally, primarily through subsidiary companies The Group invests centrally managed liquid assets in Government redenominate external borrowings into the interest rate coupon employee share incentive schemes 2002 nil.
A total of established in the markets in which the Group trades.
Due to the bonds, short-term corporate debt instruments with a minimum required for Group purposes.
The duration of these swaps matches 67 million 2002 114 million was received on employees nature of the Groups business, with patent protection on many short-term credit rating of A-1 P-1, money market funds with a the duration of the principal instruments.
Interest rate derivative exercise of share options.
Of this, option exercises satisfied from of the products in the Groups portfolio, the Groups products credit rating of AAA Aaa and preference share investments fully instruments are accounted for as hedges of the relevant assets or shares previously purchased by the ESOTs yielded 26 million compete largely on product efcacy rather than on price.
Selling collateralised with highly rated bonds.
Credit ratings shown are liabilities, where possible.
2002 58 million and option exercises satisfied from the issue margins are sufficient to cover normal operating costs and the from Standard and Poors and Moodys Investors Services The Group manages centrally the short-term cash surpluses or of new shares yielded 41 million 2002 56 million.
Groups operating subsidiaries are substantially cash generative.
borrowing requirements of subsidiary companies and uses forward The Group purchased its own shares in the market for cancellation Operating cash ow is used to fund investment in the research The Group manages its net borrowing requirements through a contracts to hedge future repayments back into the originating amounting to 980 million 2002 2,220 million.
In the period and development of new products as well as routine outows portfolio of long and medium-term borrowings, including bonds, currency.
1st January 2004 to 27th February 2004 a further 5 million of capital expenditure, tax, dividends and repayment of maturing together with short-term finance under the US dollar commercial Sensitivity analysis considers the sensitivity of the Groups net debt shares had been purchased and cancelled at a cost of 55 million.
The Group will, from time to time, have additional demands paper programme.
In 2003, a 1 billion, 3.375 per cent coupon to hypothetical changes in market rates and assumes that all other for finance, such as for share purchases and acquisitions.
bond and a 500 million, 3.25 per cent coupon bond were issued variables remain constant.
Based on the composition of net debt Future cash ow under the European Medium Term Note programme.
GlaxoSmithKline operates at relatively low levels of net debt.
at 31st December 2003 a one percentage point 100 basis points The Group expects that future operating cash ow will be In addition to the strong positive cash ow from normal trading The Groups medium-term borrowings mature at dates between increase or decrease in average interest rates would result in a sufficient to fund its operating and debt service costs, to satisfy activities, additional liquidity is readily available via its commercial 2004 and 2009, the private nancing matures in 2032, and the negligible change in the Groups annual interest expense.
normal levels of capital expenditure, to meet obligations under paper programme.
long-dated sterling bond matures in 2033.
The private nancing existing licensing agreements and to meet other routine may be redeemed by GlaxoSmithKline at any time and, in Equity risk management commitments including tax and dividends, subject to the risk The Group also has an uncommitted Euro Medium Term Note particular, on the occurrence of any event that would increase the Equity investments classied as current assets are available for sale factors discussed on pages 74 and 76.
The Group may from time programme of 5 billion, of which 2,833 million was in issue cost of funding for the Group.
During 2003 the Group also had and the Group manages disposals to meet overall business to time have additional demands for finance, such as for at 31st December 2003.
$500 million of Flexible Auction Market Preferred Stock Flex requirements as they arise.
The Group regularly monitors the value acquisitions.
The Group has access to other sources of liquidity AMPS and $400 million of Auction Rate Preference Stock ARPS of its equity investments and only enters into hedges selectively from banks and other financial institutions, in addition to the Treasury operations originally issued in 1996.
Notice to redeem the Flex AMPS and the with the approval of the Board.
cash ow from operations, for such needs.
The objective of treasury activity is to manage the post-tax net ARPS was given in February 2004, with redemption expected to cost income of financial operations to the benefit of Group be completed in March and April 2004.
Financial assets and liabilities Payment policies earnings.
Corporate Treasury does not operate as a profit centre.
An analysis of net debt is given in Note 25 to the Financial GlaxoSmithKlines long-term debt rating is AA from Standard and Group companies are responsible for monitoring and managing GlaxoSmithKline uses a variety of financial instruments, including statements, Net debt.
An analysis of financial assets and liabilities Poors and Aa2 from Moodys Investors Services.
The agencies their working capital.
The terms of sales collections and supplier derivatives, to finance its operations and to manage market risks at carrying value and fair value and a reconciliation to net debt short-term rating for paper issued under the Groups commercial payments will reect local commercial practice.
Financial instruments comprise cash and are given in Note 32 to the Financial statements, Financial paper programme is A-1 and P-1 respectively.
liquid resources, borrowings and spot foreign exchange contracts.
instruments and related disclosures, together with a discussion of In the UK, the company and each of its UK subsidiaries have derivative financial instruments and quantitative disclosures about policies to ensure that suppliers are paid on time.
In particular, A number of derivative financial instruments are used to manage Foreign exchange risk management market risk in accordance with the requirements of Financial the UK companies seek: the market risks from Treasury operations.
Derivative instruments, In GlaxoSmithKline, foreign currency transaction exposure arising Reporting Standard 13. principally comprising forward foreign currency contracts, interest on normal trade ows both in respect of external and intra-Group to settle terms of payment with suppliers when agreeing the rate and currency swaps, are used to swap borrowings and liquid trade is not hedged.
GlaxoSmithKlines policy is to minimise the The Group continues to benefit from strong positive cash ow.
terms of the transaction assets into the currencies required for Group purposes and to exposure of overseas operating subsidiaries to transaction risk Group net debt would have decreased signicantly in the year to ensure that suppliers are made aware of the agreed terms manage exposure to funding risks from changes in foreign by matching local currency income with local currency costs.
to 31st December 2003, but for the Groups purchase of its own of payment exchange rates and interest rates.
For this purpose, intra-Group trading transactions are matched shares in the market of 980 million.
to abide by the terms of payment.
centrally and intra-Group payment terms are managed to reduce GlaxoSmithKline balances the use of borrowings and liquid assets The financial assets and liabilities at 31st December 2003 are The policy includes arrangements for accelerated payment of small risk.
Exceptional foreign currency cash ows are hedged selectively having regard to: the cash ow from operating activities and representative of the treasury policies and strategies of suppliers.
under the management of Corporate Treasury.
the currencies in which it is earned: the tax cost of intra-Group GlaxoSmithKline, applied consistently during the year.
There were distributions: the currencies in which business assets are A significant proportion of Group borrowings, including the no significant changes in such policies throughout the year.
Payment performance denominated: and the post-tax cost of borrowings compared commercial paper programme, is in US dollars, to benefit from At 31st December 2003, the average number of days purchases to the post-tax return on liquid assets.
the liquidity of US dollar denominated capital markets.
Certain of ESOT share purchases and shares purchased for cancellation represented by trade and xed asset creditors of the company these and other borrowings are swapped into other currencies as Shares are held by the Trusts to satisfy future exercises of options was nil days 2002 nil days and in respect of the company and Liquid assets surplus to the immediate operating requirements required for Group purposes.
The Group seeks to denominate and awards under the Group share option and award schemes.
its UK subsidiaries in aggregate was 21 days 2002 18 days.
of Group companies are invested and managed centrally by borrowings in the currencies of its principal overseas assets.
A proportion of the shares held by the Trusts are in respect of Corporate Treasury.
Requirements of Group companies for awards where the rules of the scheme require the company to Treasury policies operating finance are met whenever possible from central Borrowings denominated in, or swapped into, foreign currencies satisfy exercises through market purchases rather than the issue resources.
that match investments in overseas Group assets are treated as a GlaxoSmithKline plc is a UK based business, reporting in sterling of new shares.
The shares held by the Trusts are matched to hedge against the relevant net assets.
and paying dividends out of sterling profits.
The role of Corporate External borrowings, mainly managed centrally by Corporate options and awards granted and diminish the dilutive effect of Treasury in GlaxoSmithKline is to manage and monitor the Groups Treasury, comprise a portfolio of long and medium-term Based on the composition of net debt at 31st December 2003 a new share issues on shareholders' capital and earnings.
external and internal funding requirements and financial risks in instruments and short-term finance.
10 per cent appreciation in sterling against major currencies would At the 2003 Annual General Meeting, shareholders renewed support of Group corporate objectives.
Treasury activities are result in a reduction in the Groups net debt of approximately GlaxoSmithKline does not hold or issue derivative financial approval for GlaxoSmithKline to make market purchases of its governed by policies and procedures approved by the Board and 128 million.
A 10 per cent weakening in sterling against major instruments for trading purposes and the Groups Treasury policies own shares.
On 23rd October 2002, GlaxoSmithKline announced monitored by a Treasury Management group.
GlaxoSmithKline currencies would result in an increase in the Groups net debt of specically prohibit such activity.
All transactions in financial a second share repurchase programme of 4 billion.
The exact maintains treasury control systems and procedures to monitor approximately 156 million.
instruments are undertaken to manage the risks arising from amount and timing of future purchases, and, following changes foreign exchange, interest rate, liquidity, credit and other financial underlying business activities, not for speculation.
in UK company law, whether repurchased shares will be held as risks.
Interest rate risk management Treasury shares rather than being cancelled, will depend on GlaxoSmithKlines policy on interest rate risk management requires market conditions and other factors.
that the amount of net borrowings at xed rates increases with the ratio of forecast net interest payable to trading profit.
74 GlaxoSmithKline Operating and financial review and prospects Operating and financial review and prospects GlaxoSmithKline 75 Outlook and risk factors Outlook Risk of loss or expiration of patents or marketing exclusivity Risk of substantial adverse outcome of litigation and Continued consolidation in the pharmaceutical industry could Patent infringement litigation government investigations adversely affect the Groups competitive position, while continued Pharmaceutical sales growth of existing products is a key driver Efforts by generic manufacturers may involve challenges to the See Note 30 to the Financial statements, Legal proceedings for consolidation among the Groups customers may increase pricing of GlaxoSmithKlines current business performance.
2004 will be validity of a patent or the assertions that their products do not a discussion of proceedings and governmental investigations in pressures.
a year of transition for GlaxoSmithKline.
The first nine months infringe the Groups patents.
If the Group is not successful, during which the Group is currently involved.
Unfavourable resolution of will be challenging as the Group absorbs the full erosion from The Group had eight products with over 600 million $1 billion in the patent protection period, in maintaining exclusive rights to these and similar future proceedings or investigations may be generics.
However, starting in the fourth quarter it is expected annual global sales in 2003.
Among these products are market one or more of its major products, particularly in the USA material to the Groups financial results.
The Group has made that there will be a return to growth as the impact of generics Paxil Seroxat and Augmentin, with respect to which the Group where the Group has its highest margins and most sales for any material provisions in 2002 and 2003 related to legal proceedings diminishes and the underlying business strength shows through.
now faces generic competition, and Wellbutrin SR, Zofran, Imitrex country, the Groups revenues and margins would be adversely and investigations which reduced its earnings.
The Group may and Avandia, with respect to which the Group is currently GlaxoSmithKline is engaged in legal proceedings regarding validity affected.
See Note 30 to the Financial statements, Legal also make material provisions related to legal proceedings or defending its intellectual property rights in the USA.
and infringement of the Groups patents relating to many of its proceedings for a discussion of patent-related proceedings in investigations in the future, which would reduce its earnings.
In products: in particular those relating to Paxil Seroxat and which the Group is involved.
many cases the practice of the plaintiff bar is to claim damages If these or any of the Groups other major products were to Wellbutrin.
These are discussed in the risk factors below and compensatory, punitive and statutory in amounts that bear no become subject to a problem such as loss of patent protection, Generic drug manufacturers are seeking to market generic versions in Note 30 to the Financial statements, Legal proceedings.
relationship to the underlying harm.
Accordingly it is potentially unexpected side effects, regulatory proceedings, publicity affecting of many of the Groups most important products, including misleading to quantify the potential exposure to claims, doctor or patient confidence or pressure from competitive GlaxoSmithKlines published earnings guidance for 2004 is to Wellbutrin, Seretide Advair, Avandia, Imitrex, Valtrex, Lamictal and proceedings and investigations of the type described in Note 30. products, or if a new, more effective treatment should be deliver EPS at constant exchange rates at least in line with Zofran, prior to the expiration of the Groups patents, and have introduced, the impact on the Groups revenues and operating business performance EPS in 2003.
As the impact of generics exhibited a readiness to do so for other products in the future.
Recent insurance loss experience, including pharmaceutical results could be significant.
In particular, the Group faces intense becomes less significant, the Group looks forward to a return Generic products competitive with Augmentin and Paxil were product liability exposures, has increased the cost of insurance competition from manufacturers of generic pharmaceutical to EPS growth in 2005. launched in the USA in 2002 and 2003, respectively, and had a coverage for pharmaceutical companies generally, including the products in all of its major markets.
significant adverse impact on the Groups overall sales and Group.
In order to contain insurance costs in 2003 and 2004 the The Group has net debt of 1.6 billion, which is low relative to earnings.
Group has adjusted its coverage prole, accepting a greater Generic products often enter the market upon expiration of its market capitalisation and this positions it to take advantage of degree of un-insured exposure.
patents or data exclusivity periods for the Groups products.
any opportunities that might arise to build the business.
Following patent expiry, the ability of generic manufacturers to Introduction of generic products typically leads to a dramatic loss obtain regulatory approval for generic versions of the Groups There are risks and uncertainties inherent in the business which Product liability litigation of sales and reduces the Groups revenues and margins for its products is also relevant.
For example, one manufacturer has may affect future performance including expected earnings The Group is currently a defendant in a number of product liability proprietary products.
The expiration dates for patents for the indicated that it expects approval for a generic version of Flonase growth.
These are discussed in Risk factors below.
lawsuits, including class actions, that involve substantial claims for Groups major products are set out on page 24. following patent expiry in the USA in mid-2004.
If approved a damages related to the Groups pharmaceutical products.
generic launch could adversely affect the Groups sales and Risk factors Governmental and payer controls earnings.
Litigation, particularly in the USA, is inherently unpredictable and Pharmaceutical products are subject to price controls or pressures There are risks and uncertainties relevant to the Groups business.
excessive verdicts that are not justied by the evidence can occur.
and other restrictions in many markets, including Japan, Germany, The factors listed below are among those that the Group thinks Weakness of intellectual property protection in certain Class actions that sweep together all persons who were prescribed France and Italy.
Some governments intervene directly in setting could cause the Groups actual results to differ materially from countries the Groups products can inate the potential liability by the force prices.
In addition, in some markets major purchasers of expected and historical results.
In some of the countries in which the Group operates, patent of numbers.
Claims for pain and suffering and punitive damages pharmaceutical products whether governmental agencies or protection may be signicantly weaker than in the USA or the are frequently asserted in product liability actions and, if allowed, private health care providers have the economic power to exert Risk that R&D will not deliver commercially successful new European Union.
In addition, in an effort to control public health can represent potentially open-ended exposure.
substantial pressure on prices or the terms of access to formularies.
products crises, some developing countries, such as South Africa and Brazil, Continued development of commercially viable new products is have considered plans for substantial reductions in the scope of Anti-trust litigation The Group cannot predict whether existing controls will increase critical to the Groups ability to replace sales of older products that patent protection for pharmaceutical products.
In particular, these In the USA it has become increasingly common that following an or new controls will be introduced that will reduce the Groups decline upon expiration of exclusive rights, and to increase overall countries could facilitate competition within their markets from adverse outcome in prosecution of patent infringement actions, margins or affect adversely its ability to introduce new products sales.
Developing new products is a costly, lengthy and uncertain generic manufacturers who would otherwise be unable to the defendants and direct and indirect purchasers and other payers profitably.
A new product candidate can fail at any stage of the introduce competing products for a number of years.
Any loss of initiate anti-trust actions as well.
Claims by direct and indirect For example, in the USA, where the Group has its highest margins process, and one or more late-stage product candidates could fail patent protection, including abrogation of patent rights or purchasers and other payers are typically led as class actions and and most sales for any country, pricing pressures could signicantly to receive regulatory approval compulsory licensing, is likely to affect adversely the Groups the relief sought may include treble damage and restitution claims.
increase upon implementation of the pharmaceutical benefit under operating results in those national markets but is not expected to New product candidates may appear promising in development Medicare, or in the event that state programmes to control the be material to the Group overall.
Absence of adequate patent Governmental investigations but, after significant investments, fail to reach the market or have cost of pharmaceuticals, are adopted.
Once the Medicare protection could limit the opportunity to look to such markets The Group is responding to federal and state governmental only limited commercial success as a result of efficacy or safety programme initiates outpatient pharmaceutical coverage for its for future sales growth.
investigations in the USA into pricing, marketing and concerns, inability to obtain necessary regulatory approvals, beneciaries, the US government, or the private insurers which will reimbursement of a number of prescription drug products.
These difficulty or excessive costs to manufacture, infringement of offer coverage, through their enormous purchasing power under investigations could result in related restitution or civil false claims patents or other intellectual property rights of others or inability the programme, could demand discounts that may implicitly create act litigation on behalf of the federal or state governments and to differentiate the product adequately from those with which it price controls on prescription drugs.
Additionally, a number of related proceedings initiated against GlaxoSmithKline by or on competes.
The successful development of the Groups research states have proposed or implemented various schemes to control behalf of consumers and private payers.
and development pipeline is of particular importance in light of prices for their own senior citizens drug programmes, including the recent and anticipated expiration of patent or data exclusivity importation from other countries and bulk purchasing of drugs.
Risks of competition, price controls and limitations on sales for a number of the Groups largest selling products.
The growth in the number of patients covered through large Third party competition managed care institutions in the USA, which would be likely to The Group operates in highly competitive businesses.
In the increase with implementation of the Medicare amendments, also pharmaceuticals business, it faces competition both from increases pricing pressures on the Groups products.
These trends proprietary products of large international manufacturers and may adversely affect the Groups revenues and margins from sales producers of generic pharmaceuticals.
significant product in the USA.
Until the terms of implementation of the Medicare innovations, technical advances or the intensification of price pharmaceutical benefit have been nalised, it is not possible to competition by competitors could adversely affect the Groups quantify the impact of that benefit on the Groups financial results.
76 GlaxoSmithKline Operating and financial review and prospects Operating and financial review and prospects GlaxoSmithKline 77 2002 Year Regulatory controls Global political and economic conditions In accordance with US SEC disclosure requirements, the following Sales of Wellbutrin, for depression, grew 42 per cent to The Group must comply with a broad range of regulatory controls The Group conducts a substantial portion of its operations outside discussion compares results for the year to 31st December 2002 882 million, reecting increased physician awareness of the on the testing, approval, manufacturing and marketing of many the UK.
Fluctuations in exchange rates between sterling and other with the results for the year to 31st December 2001. products outstanding efcacy and favourable side effect prole.
In of its pharmaceutical and consumer healthcare products, currencies, especially the US dollar, the Euro and the Japanese Yen, 2002, an application for approval of a once-daily formulation, All growth rates included in the review of turnover are at constant particularly in the USA and countries of the European Union, that materially affect the Groups financial results.
Wellbutrin XL, was submitted to the FDA.
exchange rates CER unless otherwise stated.
The sterling growth affect not only the cost of product development but also the time The Group has no control over changes in ination and interest rates may be found in the table of pharmaceutical sales by GlaxoSmithKlines medicine for epilepsy, Lamictal, continued required to reach the market and the uncertainty of successfully rates, foreign currency exchange rates and controls or other therapeutic area on page 78. to grow across all regions achieving sales of 438 million, up doing so.
economic factors affecting its businesses or the possibility of 27 per cent.
In 2002, the Group led an sNDA for Lamictal seeking Strict regulatory controls also heighten the risk of withdrawal by political unrest, legal and regulatory changes or nationalisation Exchange the first-ever indication for long-term management of depressive regulators of an approval previously granted, which would reduce in jurisdictions in which the Group operates.
These factors could episodes in bipolar disorder.
The currencies that most inuence the Groups results are the US revenues and can result in product recalls and product liability materially affect the Groups future results of operations.
Dollar, the Euro and the Japanese Yen.
In addition, in some cases the Group may voluntarily Respiratory cease marketing a product for example the withdrawal of Accounting standards The pound hit its highest level against the dollar for more than GlaxoSmithKline continued to be the global leader in respiratory Lotronex shortly after its initial launch in the USA or face declining New or revised accounting standards and rules promulgated from two-and-a-half years, climbing above $1.61 and the Euro gained pharmaceuticals with sales of its three key products sales based on concerns about efcacy or safety, whether or not time to time by UK, US or International accounting standard- 17.7 per cent against the dollar in 2002, the first year that the Seretide Advair, Flixotide Flovent and Serevent - amounting to scientically justied, even in the absence of regulatory action.
setting boards could have a material adverse impact on the dollar has fallen in value against the euro, as investors weighed nearly 3 billion, up 25 per cent.
Developments in the post-approval adverse event prole for a Groups reported financial results.
The Group believes that it up the impact of possible war in Iraq, tensions with North Korea Sales of Seretide Advair, GlaxoSmithKlines second largest product, product or the product class may have a major impact on the complies with the appropriate regulatory requirements concerning and fears for the US economy.
grew 96 per cent to 1.6 billion although this contributed to marketing and sale of the product.
its financial statements and disclosures.
However, other companies Pharmaceutical sales declines in Serevent and Flixotide, its constituent products.
Advair have experienced investigations into potential non-compliance became the US asthma market leader in new prescriptions after Concentration of sales to wholesalers with accounting and disclosure requirements that have resulted Total pharmaceutical sales in 2002 were 17,995 million compared less than two years on the market.
Seretide also continued to In the USA, in line with other pharmaceutical companies, the in significant penalties.
to 17,205 million in 2001, an increase of eight per cent.
perform strongly in Europe, up 36 per cent, and International Group sells its products through a small number of wholesalers Less than one per cent of this overall growth came from price markets up 92 per cent.
In December 2002, GlaxoSmithKline in addition to hospitals, pharmacies, physicians and other groups.
Growth in sterling terms of five per cent was signicantly led an NDA for Ario for COPD.
The Group is exposed to a concentration of credit risk to these impacted by the weakness of the US dollar and other currencies.
wholesalers that, if affected by financial difficulty, could materially Within the Groups portfolio, sales of new products, those Anti-virals and adversely affect the Groups financial results.
launched in a major market within the last five years, accounted HIV medicines grew across all regions and totalled 1.5 billion in for 27 per cent of total sales and grew by 36 per cent to sales, up 13 per cent.
Sales of Trizivir, GlaxoSmithKlines triple Environmental liabilities 4,785 million.
Sales of the more established, franchise products combination therapy, grew 95 per cent to 315 million.
The environmental laws of various jurisdictions impose actual and amounted to 9,772 million representing 54 per cent of total sales potential obligations on the Group to remediate contaminated Valtrex, for herpes, continued to benefit from its convenient and grew six per cent compared to last year.
The Group has also been identied as a potentially once-daily dosing for suppressive therapy and achieved strong products, now less actively promoted, were 3,438 million, a responsible party under the US Comprehensive Environmental sales growth of 26 per cent worldwide and 35 per cent in the decline of 11 per cent representing 19 per cent of total sales.
Response Compensation and Liability Act at a number of sites for USA.
In October 2002, GlaxoSmithKline led an sNDA for Valtrex remediation costs relating to the Groups use or ownership of Global pharmaceutical sales in the fourth quarter of 2002 grew seeking the first-ever indication to reduce the risk of transmission such sites.
Failure to properly manage the environmental risks seven per cent, reecting US sales growth of 14 per cent to of genital herpes.
In December 2002, GlaxoSmithKline led an could result in additional remedial costs that could materially 2,592 million: whereas in Europe sales growth was weaker at NDA for 908, a protease inhibitor, for the treatment of HIV.
The and adversely affect the Groups operations.
See Note 30 to the one per cent with sales of 1,272 million, and in International decline in Zovirax sales reected transfers to the newer Valtrex Financial statements, Legal proceedings for a discussion of sales were at at 935 million.
 proceedings in which the Group is involved.
Pharmaceutical sales by therapeutic area Anti-bacterials Reliance on information technology Anti-bacterial sales declined 12 per cent worldwide and 22 per Across the Groups portfolio of products, six major therapeutic The Group is increasingly dependent on information technology cent in the USA.
Augmentins US sales were down 20 per cent areas experienced good growth for the year, including the fast systems, including internet based systems, for internal in the year as a result of generic competition that began in the growing franchises: CNS 4.5 billion up 17 per cent, respiratory communication as well as communication with customers and third quarter.
Four generic versions of Augmentin have been 4.0 billion up 16 per cent, anti-virals 2.3 billion up 12 per cent suppliers.
Any significant disruption of these systems, whether introduced in the USA following a decision by the US District and vaccines 1.1 billion up 16 per cent.
due to computer viruses or other outside incursions, could Court for Eastern Virginia that held invalid GlaxoSmithKlines materially and adversely affect the Groups operations.
patents on Augmentin expiring in 2002, 2017 and 2018.
US Central nervous system sales of Ceftin declined 80 per cent due to generic competition Sales of Seroxat Paxil, GlaxoSmithKlines leading product for Taxation which began during the first quarter, 2002. depression and anxiety disorders, was the driver of growth in the The effective tax rate on the Groups earnings benets from the CNS therapy area, with sales of 2 billion, up 15 per cent globally fact that a portion of its earnings is taxed at more favourable and 18 per cent in the USA.
International sales of Paxil grew rates in some jurisdictions outside the United Kingdom.
Changes 27 per cent to 267 million led by continued strong growth in in tax laws or in their application with respect to matters, such as Japan.
Launched in April 2002, Paxil CR continued to gain transfer pricing and the risk of double taxation, that relate to the acceptance due to its strong tolerability prole.
portion of the Groups earnings taxed at more favourable rates, could increase the Groups effective tax rate and adversely affect its financial results.
The Group is involved in a significant dispute with the US Internal Revenue Service over transfer pricing.
These matters are discussed in Note 12 to the Financial statements, Taxation.
78 GlaxoSmithKline Operating and financial review and prospects Operating and financial review and prospects GlaxoSmithKline 79 Pharmaceutical sales by therapeutic area 2002 Metabolic Sales in the anti-virals therapeutic area grew 18 per cent, led by Worldwide sales for the metabolic category were 960 million.
a strong performance of Trizivir, up 82 per cent, which partially Total USA Europe International The Avandia franchise Avandia and Avandamet grew 19 per cent drew sales from its constituent products, and Valtrex, up Therapeutic area % of 2002 2001 Growth 2002 Growth 2002 Growth 2002 Growth for the year with US sales up 15 per cent to 688 million.
major products total 0 500 1,000 1,500 2,000 2,500 3,000 3,500 4,000 m m % m CER% % m CER% % m CER% % CER% Avandamet, a combination of Avandia and metformin HCI, Sales of Avandia increased by 15 per cent, benefiting from the CNS 4,511 4,007 17 13 3,305 21 17 770 2 1 436 19 11 25 Depression 2,937 2,504 22 17 2,275 26 21 375 2 1 287 26 17 expanded the Avandia metabolic franchise with its US launch in launch of Avandamet in November 2002.
Avandamet for the treatment of type 2 declined as Augmentin started to experience generic competition Wellbutrin 882 647 42 36 862 43 37 - - - 20 19 5 diabetes is the first medicine that targets insulin resistance and in the second half of the year.
In the cardiovascular franchise, decreases glucose production in one convenient pill.
Since its Coreg sales increased to 295 million reecting improved market Migraine 888 849 8 5 670 11 6 161 3 2 57 12 6 Imigran Imitrex 798 758 9 5 616 12 7 133 3 2 49 11 4 approval by the FDA in May 1999, Avandia has been used by over share.
Naramig Amerge 90 91 1 1 54 2 2 28 3 3 8 17 14 four million patients worldwide.
Europe Lamictal 438 355 27 23 247 44 38 151 7 9 40 18 8 Vaccines Europe region contributed 26 per cent of pharmaceutical sales.
Requip 89 75 21 19 47 39 31 38 4 6 4 23 33 Zyban 99 129 21 23 47 10 13 27 36 36 25 20 24 Sales of vaccines grew 16 per cent to over 1 billion, supported Although overall sales growth in the region was only two per cent, by the Hepatitis franchise, up 12 per cent to 483 million.
Total good growth was recorded in several markets including Spain and Respiratory 3,987 3,537 16 13 2,023 28 23 1,341 4 5 623 10 1 22 vaccine sales in Europe grew 17 per cent.
US sales grew Central and Eastern Europe, but government healthcare reforms, Flixotide Flovent, 16 per cent from the launch of Twinrix and continued growth in including pricing and reimbursement restrictions, adversely Serevent, Seretide Advair 2,937 2,410 25 22 1,557 38 32 1,018 8 10 362 27 20 Seretide Advair 96 1,631 850 92 876 100 100 608 36 38 147 92 81 Havrix, driven by new state mandates requiring Hepatitis A affected sales in Italy.
Infanrix, GlaxoSmithKlines Serevent 523 645 17 19 294 20 23 191 15 15 38 4 3 DTPa range of combination vaccines, grew eight per cent to International Flixonase Flonase 534 504 10 6 413 15 10 52 6 4 69 1 9 Ventolin 10 254 million.
A four per cent sales growth in the International region reected 265 306 13 8 73 72 133 2 1 124 4 13 Becotide 130 161 18 19 105 15 14 25 30 36 a mixture of good growth in the Middle East and Africa, Canada Cardiovascular and urogenital and Asia Pacic and a decline in sales in Latin America, principally Anti-virals 13 2,299 2,128 12 8 1,213 18 13 636 8 450 4 7 6 In 2002, Coreg sales grew 27 per cent to 306 million, benefiting because of poor economic conditions in Mexico and Brazil.
Epivir 295 302 1 2 164 6 2 94 1 37 20 2 11 Retrovir 50 55 6 9 23 2 4 17 15 15 10 2 9 In November 2002, Levitra vardenal a new agent for the Overall International growth was driven by Seretide, Seroxat Paxil, Ziagen 173 167 10 4 101 7 3 53 2 4 19 51 6 treatment of erectile dysfunction, received a positive opinion from Avandia and vaccines, partly offset by declines in Zantac and Agenerase 44 50 8 12 31 15 18 9 12 13 4 16 the European CPMP.
The FDA issued an approvable letter for Zovirax.
Levitra was researched and developed by Bayer AG The Asia Pacic area grew due to the performance of Seretide Valtrex 425 350 26 21 275 35 30 73 4 6 77 20 12 and will be co-promoted with GlaxoSmithKline.
Strong growth in a number of markets was partly Zovirax 228 296 21 18 19 23 34 17 67 24 24 127 23 offset by lower growth in the largest market, Australia, reecting Oncology and emesis Zeffix 123 103 23 19 12 69 71 16 34 33 95 18 13 reduced sales of Zyban and Zantac.
Sales of Zofran grew 22 per cent to 708 million, driven by a Anti-bacterials 12 2,210 2,604 12 15 975 22 25 696 2 1 539 4 10 strong US performance, up 28 per cent to 525 million.
The market growth in Japan reected strong growth of Paxil and Augmentin 1,421 16 23 2 8 1,191 14 704 20 315 3 172 3 Flixotide Flovent partly offset by the decline of the older product Zinnat Ceftin 243 409 39 41 34 80 81 117 5 5 92 8 13 Other therapeutic areas Zantac, and government price reductions.
Fortum 201 209 1 4 37 6 10 96 4 4 68 5 11 Sales of Relafen for arthritis, fell reecting generic competition in Amoxil 136 149 5 9 32 9 3 45 12 10 59 7 13 The Middle East and Africa area followed the trends of most other the USA.
markets with growth in Seretide, Avandia, vaccines and HIV.
USA Hepatitis 483 445 12 9 211 18 13 204 10 11 68 2 9 10 16 The USA reported 13 per cent sales growth in the year and this Infanrix 254 238 8 7 79 14 117 1 58 18 Consumer Healthcare sales business currently represents 54 per cent of total pharmaceutical 2002 2001 Growth 8 Oncology and emesis 977 838 21 17 740 26 21 152 5 7 85 5 sales.
Sales growth in the central nervous system products of m m CER% % 601 22 18 525 28 8 2 Zofran 708 23 117 7 8 66 21 per cent was driven by Wellbutrin, reecting increased OTC medicines 1,586 1,603 4 1 94 90 7 4 63 10 5 24 3 4 7 2 Hycamtin prescribing by primary care physicians and psychiatrists, and Paxil Analgesics 339 354 2 4 following the launch of the CR formulation in April 2002.
Lamictal, Cardiovascular and Dermatological 188 190 5 1 4 18 13 16 10 661 591 15 12 436 147 7 9 78 urogenital indicated for epilepsy, recorded sales growth of 44 per cent.
Gastro-intestinal 312 342 1 9 306 251 27 22 295 27 22 11 27 22 Coreg Advair maintained its strong growth with sales of 876 million Respiratory tract 142 145 1 2 driving the overall respiratory sales growth of 28 per cent.
Other 1,310 1,677 18 22 127 56 58 407 11 12 776 9 15 7 Smoking control 378 337 16 12 Zantac 382 505 21 24 86 16 19 116 30 28 180 18 24 However this adversely affected sales of its constituent products, Natural wellness support 162 158 5 3 Flovent and Serevent, which both showed declines.
3,217 3,284 2 2 CER represents sales growth at constant exchange rates and at actual exchange rates.
Certain products have been reclassified into different therapeutic areas for comparative purposes.
80 GlaxoSmithKline Operating and financial review and prospects Operating and financial review and prospects GlaxoSmithKline 81 OTC medicines Trading profit profit on ordinary activities before taxation - statutory results profit before taxation - business performance Smoking control sales growth was driven by the performance of Statutory trading profit was 5,662 million with a growth of Taking into account net other operating expense in 2002 and net The analysis and discussion below of profit before taxation relates Nicoderm Niquitin Nicabate.
In the USA Nicoderm grew strongly 26 per cent, stronger than sales growth of seven per cent, other operating income in 2001, the contribution from associates, to business performance.
despite competition from private label and the launch of demonstrating an improved trading margin of 3.8 percentage business disposals and net interest payable, statutory profit before 2002 2001 competitor patches.
The NiQuitin Lozenge, Commit, was points to 26.7 per cent compared with 2001.
This was principally tax was 5,506 million, compared with 4,517 million in 2001, an Other operating income expense m m launched in the USA, in November 2002.
Clinical studies show due to cost savings derived from merger integration, increase of 28 per cent.
Royalties and other income 75 34 that Commit can help smokers who have tried to quit before.
In manufacturing and other initiatives and lower costs of Other operating expense 209 126 analgesics Panadol recorded good sales growth of five per cent implementing these initiatives.
Trading profit business performance CER two per cent sterling, partly offset by declines in a number 134 92 To illustrate GlaxoSmithKlines business performance in 2002, the of other brands.
Abreva in the USA and Zovirax in Europe, both profit before taxation - statutory results Income from equity investments and analysis below of trading profit and the subsequent discussion for the treatment of cold sores, drove dermatological sales other disposals 23 129 2002 2001 excludes merger items, integration and restructuring costs and the Other operating income expense m m growth of five per cent CER one per cent sterling decline.
Management believes that exclusion of gastro-intestinal, sales of Citrucel rose by 19 per cent CER 15 Royalties and other income 75 34 these items provides a better reection of the way in which the per cent sterling, but this was offset by declines in Tums and Other operating income expense includes litigation costs and Other operating expense 209 126 business is managed.
Accordingly this information is provided as a Tagamet.
provisions relating to legal claims on withdrawn products, product 134 92 supplement to that contained in the consolidated statement of withdrawals and anti-trust matters, equity investment carrying Income from equity investments and profit and loss on pages 88 and 89 prepared in accordance with Oral care value adjustment arising from stock market price changes, royalty other disposals 23 129 UK GAAP.
Oral care sales grew marginally in Europe but declined in the income, product disposals and equity investment sales.
Other 111 37 2002 2001 Growth highly competitive US market.
Overall Oral care sales declined operating expenses were 111 million in the year compared with m % m % CER% % two per cent, principally as a result of reduced Aquafresh sales: 37 million income in 2001.
The year on year movement reects Other operating income expense includes litigation costs and Sales 21,212 100.0 20,489 100.0 7 4 although an increase in Sensodyne sales partially offset this.
higher provisions in 2002 for product liability and other claims, and provisions relating to legal claims on withdrawn products, lower 2002 proceeds from disposals and equity investment sales.
Cost of sales 4,243 20.0 4,430 21.6 2 4 product withdrawals and anti-trust matters, equity investment Nutritional healthcare Selling, general carrying value adjustments arising from stock market price In Nutritional healthcare Lucozade and Ribena reported strong profit on disposal of interest in associate and administration 7,543 35.5 7,451 36.4 5 1 changes, royalty income, product disposals and equity growth in Europe, driven by increased availability and promotion.
There were no disposals of interest in associates in 2002.
In 2001 Research and investment sales.
Horlicks sales declined primarily in International markets.
the Group sold 1.5 million shares in Quest Diagnostics, Inc. development 2,732 12.9 2,555 12.5 9 7 Other operating expenses were 111 million in the year realising a gain of 96 million.
Trading profit 6,694 31.6 6,053 29.5 15 11 Trading profit statutory results compared with 37 million income in 2001.
The year on year movement reects higher provisions in 2002 for product liability Share of profits losses of joint ventures and associated The analysis and discussion below relates to statutory Cost of sales and other claims, and lower 2002 proceeds from disposals and undertakings performance.
Statutory results include merger items, integration Cost of sales reduced as a percentage of sales as a result of benets equity investment sales.
The share of profits of associates arises principally from the Groups and restructuring costs, and the disposal of subsidiaries.
arising from merger and manufacturing restructuring savings, holding in Quest Diagnostics, Inc. 2002 2001 Growth movements in stock provisions and a favourable regional mix.
profit on disposal of interest in associate 2002 2001 m % m % CER% % Net interest payable m m There were no disposals of interest in associates in 2002.
In Selling, general and administration Sales 21,212 100.0 20,489 100.0 7 4 2001 the Group sold 1.5 million shares in Quest Diagnostics, Inc. Interest payable 206 198 Selling, general and administration costs benefited from cost savings realising a gain of 96 million.
Cost of sales 4,609 21.7 4,733 23.1 3 Investment income 73 129 arising from merger integration implementation and other cost saving Selling, general 133 69 programmes including local restructuring in Europe and International Share of profits losses of joint ventures and associated and administration 8,041 37.9 8,408 41.1 1 4 Share of interest payable of associate 8 19 regions.
undertakings Research and 141 88 The share of profits of associates arises principally from the development 2,900 13.7 2,651 12.9 12 9 Research and development Groups holding in Quest Diagnostics, Inc. Trading profit 5,662 26.7 4,697 22.9 26 21 Net interest payable increased compared with 2001 largely as a Research and development R&D increased nine per cent, result of a higher average level of net debt driven by the use of cash reecting increased clinical trial and in-licensing activity and the Disposal of business Cost of sales to fund the Groups share buy-back programme.
The benefit of a reinvestment of merger synergies.
Pharmaceuticals R&D The profit on product divestments and disposal of business in 2002 Cost of sales reduced as a percentage of sales as a result of benets smaller number of shares in issue is reected in earnings per share.
expenditure represented 14.6 per cent of pharmaceutical sales of 21 million reects the final settlements regarding merger arising from merger and manufacturing restructuring savings, in the year.
related product disposals and the disposal of the Healthcare movements in stock provisions and a favourable regional mix.
profit on ordinary activities before taxation - business Services business in 1999. performance Trading profit Selling, general and administration 2002 2001 Other operating income expense, together with the disposal of Business performance trading profit was 6,694 million with a Net interest payable m m Selling, general and administration costs benefited from lower part of the interest in an associate in 2001, reduced profit by growth of 15 per cent, stronger than sales growth of seven Interest payable 206 198 merger integration costs, cost saving programmes from merger 111 million in 2002, but added 133 million to profit in 2001. per cent, demonstrating an improved trading margin of 2.1 Investment income 73 129 integration implementation and other initiatives including local Taking account of the contribution from associates and net interest percentage points to 31.6 per cent compared with 2001.
This was restructuring in Europe and International regions.
133 69 payable, business performance profit before tax was 6,517 million, principally due to cost savings derived from merger integration, Share of interest payable of associate 8 19 compared with 6,169 million in 2001, an increase of 11 per cent.
Research and development 141 88 Research and development R&D increased 12 per cent, reecting increased merger integration costs, higher clinical trial and in-licensing activity and the reinvestment of merger synergies.
Pharmaceuticals R&D expenditure represented 15.5 per cent of pharmaceutical sales in the year.
